We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
RANDOX LABORATORIES

Download Mobile App




Novel Fecal Biomarker Found for Colorectal Cancer

By LabMedica International staff writers
Posted on 17 Oct 2018
Print article
Image: The LightCycler 480 II is a high-performance, medium- to high-throughput PCR platform (Photo courtesy of Roche).
Image: The LightCycler 480 II is a high-performance, medium- to high-throughput PCR platform (Photo courtesy of Roche).
Colorectal cancer (CRC) is a lethal disease that has been rising in incidence during recent decades, placing an increasingly important burden on the healthcare system worldwide and gut microbial dysbiosis contributes to the development of this deadly disease.

Conventionally, “beneficial” Lactobacillus (Lb) and Bifidobacterium (Bb) have been employed as probiotics in humans, having displayed anti-carcinogenic effects in animal models. Faecalibacterium prausnitzii (Fp), the sole known species of Faecalibacterium, is an anti-inflammatory commensal anaerobe.

Scientists at the Sun Yat-sen University (Guangzhou, China) and their colleagues measured the relative abundance of Fusobacterium nucleatum (Fn), Faecalibacterium prausnitzii (Fp), Bifidobacterium (Bb), and Lactobacillus (Lb) by quantitative polymerase chain reaction (PCR) in fecal samples from two cohorts of 903 individuals. They evaluated and validated the diagnostic performance of these microbial ratios and investigated the antagonistic effect of Fn against three different indicator stains.

The quantification of the microbiomes' target and reference gene (universal 16S rDNA) was performed in triplicate on a LightCycler 480 II using an SYBR Green-based assay. The minimum inhibitory concentration (MIC) of the cell-free culture supernatants (CFSs) was determined according to the standard broth microdilution method. Flow cytometric measurements were performed on a flow cytometer.

The team reported that the microbial ratio of Fn to Bb (Fn/Bb) had a superior sensitivity of 84.6% and specificity of 92.3% in detecting CRC (area under the curve, AUC = 0.911). The combination of Fn/Bb and Fn/Fp improved the diagnostic value (AUC = 0.943). Moreover, the combination of Fn/Bb and Fn/Fp offered 60.0% specificity and 90.0% sensitivity in detecting stage I of CRC (AUC = 0.804). In particular, Fn was negatively correlated with Fp in the CRC group. The performance for CRC diagnosis was confirmed in the validation cohort II. The culture supernatant from Fn exhibited strong bactericidal activity against probiotics Fp and Bb strains.

The authors concluded that Fn could play a role in microbiota dysbiosis via the secreted antagonistic substances against probiotics. Moreover, the ratio of Fn to the important probiotics Fp and Bb was identified as a valuable biomarker for screening early CRC. The study was published in the September 2018 issue of the journal Clinical Chemistry.

Related Links:
Sun Yat-sen University

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
POCT Fluorescent Immunoassay Analyzer
FIA Go
New
Gold Member
Magnetic Bead Separation Modules
MAG and HEATMAG

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Pathology

view channel
Image: The new method could reduce undiagnosed cancer cases in less-developed regions (Photo courtesy of 123RF)

New Method Offers Sustainable Approach to Universal Metabolic Cancer Diagnosis

Globally, more than one billion people suffer from a high rate of missed disease diagnosis, highlighting the urgent need for more precise and affordable diagnostic tools. Such tools are especially crucial... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.